Suppr
超能文献

Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?

作者信息

van Heeckeren Willem J, Ortiz Jose, Cooney Matthew M, Remick Scot C

出版信息

J Clin Oncol. 2007 Jul 20;25(21):2993-5. doi: 10.1200/JCO.2007.11.5113.

DOI:10.1200/JCO.2007.11.5113

PMID:17634476

Abstract

摘要

相似文献

Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?

J Clin Oncol. 2007 Jul 20;25(21):2993-5. doi: 10.1200/JCO.2007.11.5113.

Hypertension and proteinuria: a class-effect of antiangiogenic therapies.

Anticancer Drugs. 2009 Jan;20(1):81-2. doi: 10.1097/CAD.0b013e3283161012.

Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.

Expert Rev Anticancer Ther. 2009 Oct;9(10):1413-6. doi: 10.1586/era.09.116.

Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway.

Cancer Treat Rev. 2011 Aug;37(5):344-52. doi: 10.1016/j.ctrv.2011.02.002. Epub 2011 Mar 23.

Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy.

Expert Opin Drug Metab Toxicol. 2012 Mar;8(3):283-93. doi: 10.1517/17425255.2012.656845. Epub 2012 Jan 30.

Response to anti-angiogenesis: an ever changing feature.

Breast. 2011 Oct;20 Suppl 3:S61-2. doi: 10.1016/S0960-9776(11)70296-X.

Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.

J Clin Oncol. 2009 Sep 1;27(25):4169-76. doi: 10.1200/JCO.2008.18.8193. Epub 2009 Jul 27.

Antiangiogenic therapy for cancer: an update.

Cancer J. 2007 Nov-Dec;13(6):345-8. doi: 10.1097/PPO.0b013e31815a7b69.

Retinal anti-angiogenesis by a new route.

Nat Biotechnol. 2008 May;26(5):528-9. doi: 10.1038/nbt0508-528.

Proteinuria and VEGF-targeted therapies:  an underestimated toxicity?

J Nephrol. 2013 Sep-Oct;26(5):807-10. doi: 10.5301/jn.5000307. Epub 2013 Aug 7.

引用本文的文献

Exploitation of enhanced prime editing for blocking aberrant angiogenesis.

J Adv Res. 2025 Jun;72:121-133. doi: 10.1016/j.jare.2024.07.006. Epub 2024 Jul 10.

Anti-Angiogenic Therapy: Albumin-Binding Proteins Could Mediate Mechanisms Underlying the Accumulation of Small Molecule Receptor Tyrosine Kinase Inhibitors in Normal Tissues with Potential Harmful Effects on Health.

Diseases. 2021 Apr 10;9(2):28. doi: 10.3390/diseases9020028.

Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial.

Ann Transl Med. 2020 Sep;8(17):1047. doi: 10.21037/atm-20-2990.

Expression of fibroblast growth factor receptor 4 and clinical response to lenvatinib in patients with anaplastic thyroid carcinoma: a pilot study.

Eur J Clin Pharmacol. 2020 May;76(5):703-709. doi: 10.1007/s00228-020-02842-y. Epub 2020 Feb 7.

Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma.

Int J Mol Sci. 2017 Aug 10;18(8):1736. doi: 10.3390/ijms18081736.

Analysis of adverse events of sunitinib in patients treated for advanced renal cell carcinoma.

Arch Med Sci. 2016 Apr 1;12(2):360-4. doi: 10.5114/aoms.2016.59262. Epub 2016 Apr 12.

Cardiovascular Toxicity of Molecular Targeted Therapy in Cancer Patients: A Double-Edged Sword.

Acta Cardiol Sin. 2013 Jul;29(4):295-303.

Retrospective analysis of bevacizumab-induced hypertension and clinical outcome in patients with colorectal cancer and lung cancer.

Cancer Med. 2016 Jul;5(7):1381-7. doi: 10.1002/cam4.701. Epub 2016 Apr 25.

Targeting prion-like protein doppel selectively suppresses tumor angiogenesis.

J Clin Invest. 2016 Apr 1;126(4):1251-66. doi: 10.1172/JCI83427. Epub 2016 Mar 7.

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients.

Br J Cancer. 2015 Dec 1;113(11):1571-80. doi: 10.1038/bjc.2015.368. Epub 2015 Oct 22.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译